4-(2-(dimethylamino)ethoxy)benzene-1,2-diamine | 115155-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2-(dimethylamino)ethoxy)benzene-1,2-diamine
• 英文别名: 4-[2-(dimethylamino)ethoxy]benzene-1,2-diamine
• CAS: 115155-90-3
• 化学式: C₁₀H₁₇N₃O
• 分子量: 195.264
• InChiKey: FOQMUVRIBLMRNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  357.6±32.0 °C(Predicted)
• 密度：
  1.117±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  64.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-(dimethylamino)ethoxy)benzene-1,2-diamine 、 对苯二甲醛 在 sodium metabisulfite 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 0.75h， 生成 2,2'-((2,2'-(1,4-phenylene)bis(1H-benzo[d]imidazole-6,2-diyl))bis(oxy))bis(N,N-dimethylethanamine)
  参考文献：
  名称：

  [EN] BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME
  [FR] COMPOSÉS BIS-BENZIMIDAZOLE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2019099777A8
• 作为产物：
  描述：

  5-(2-(dimethylamino)ethoxy)-2-nitroaniline 在 氢气 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以gave 4-(2-Dimethylamino-ethoxy)-benzene-1,2-diamine as a dark yellow oil (0.665 g, 90%)的产率得到4-(2-(dimethylamino)ethoxy)benzene-1,2-diamine
  参考文献：
  名称：

  IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES

  摘要：

  本发明提供了式（I）的化合物及其盐，互变异构体，溶剂合物和N-氧化物；其中Q为CH或N；X为N，N+—O−或CR3；Y为N，N+—O−或CR3a；R1和R2分别选自氢和定义在权利要求中的各种取代基；或者R1和R2与它们附着的原子一起连接形成一个可选取代的4到7个成员的碳环芳香族或杂环芳香族或非芳香族环；R3选自氢和各种取代基；而R3a选自氢和定义在权利要求中的各种取代基。还提供了含有式（I）化合物的药物组合物，制备化合物的过程以及化合物的医药用途。式（I）化合物具有作为CDK激酶抑制剂的活性，并可用于治疗增殖性疾病，如癌症等。

  公开号：

  US20120101064A1

文献信息

• [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION COMME MODULATEURS DES KINASES DÉPENDANTES DES CYCLINES
  申请人：NOVARTIS AG

  公开号：WO2010125402A1

  公开（公告）日：2010-11-04

  The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

  该发明提供了式(I)的化合物及其盐、互变异构体、溶剂合物和N-氧化物；其中Q为CH或N；X为N、N+-O-或CR3；Y为N、N+-O-或CR3a；R1和R2分别选自氢和各种定义中的取代基；或R1和R2与它们连接的原子一起，形成一个可选择地取代的含氢碳环或杂环芳香或非芳香环，成员数为4到7；R3选自氢和各种取代基；R3a选自氢和各种定义中的取代基。还提供了含有式(I)的化合物的药物组合物，制备该化合物的方法以及该化合物的医药用途。式(I)的化合物具有作为CDK激酶抑制剂的活性，并可用于治疗癌症等增殖性疾病。
• JAK-2 modulators and methods of use
  申请人：Exelixis, Inc.

  公开号：US08088767B2

  公开（公告）日：2012-01-03

  This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.

  本发明涉及蛋白酪氨酸激酶及其抑制剂领域。具体来说，本发明涉及JAK-2的抑制剂、用于抑制JAK-2的化合物的制药组合物、在细胞中抑制JAK-2的方法，包括将需要抑制JAK-2的细胞与本发明的化合物或制药组合物中含有的化合物接触。本发明还包括治疗涉及JAK-2的疾病或病症的方法，包括向患者投与本发明的化合物组成的制药组合物。
• JAK-2 Modulators and Methods of Use
  申请人：Galan Adam Antoni

  公开号：US20100136136A1

  公开（公告）日：2010-06-03

  This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.

  本发明涉及蛋白酪氨酸激酶及其抑制剂领域。具体而言，本发明涉及JAK-2的抑制剂，以及用于抑制JAK-2的化合物的制药组合物，包括通过将含有本发明化合物的化合物或制药组合物与需要抑制JAK-2的细胞接触来抑制JAK-2的细胞方法。本发明还包括治疗涉及JAK-2的疾病或病状的方法，包括向患者施用包含本发明化合物的制药组合物。
• RADIOPROTECTOR COMPOUNDS AND METHODS
  申请人：Martin Roger Francis

  公开号：US20130109678A1

  公开（公告）日：2013-05-02

  The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection). Preferred compounds of the invention are those of Formula II, as follows: wherein W represents —N(R 1 R 2 ) where R 1 and R 2 are not both hydrogen and where they may together form a 5, 6 or 7 membered ring structure, —NHN(R 1 R 2 ), —NHR 3 N(R 1 R 2 ), —NHR 3 OR 2 , —N(R 3 )R 3 OR 2 , —N(R 1 )R 3 OR 3 OR 3 , —OR 3 NR 1 R 2 , —OR 3 or W represents piperidyl, piperazinyl, morpholinyl, thiomorpholinyl or diazepanyl each of which may be optionally substituted by C 1 to C 4 alkyl, C 2 to C 4 alkenyl, —N(CO)N(R 1 R 2 ), —N(CO)OR 1 , —N(CO)OR 3 OH, —(CO)NR 1 R 2 , —R 3 (CO)NR 1 R 2 , —R 3 OR 1 , —OR 1 , —N(R 1 R 2 ) or —NH—; R 1 and R 2 are the same or different and are selected from hydrogen, C 1 to C 4 alkyl or C 2 to C 4 alkenyl; R 3 is a C 1 to C 4 alkyl or C 2 to C 4 alkenyl group or chain; Z is the same or different and represents N or CH; Z′ is the same or different and represents N or C; X represents CH, N or NH, where is a double bond when X is CH or N and a single bond when X is NH; X′ represents N or NH, wherein when X is CH or NX′ is NH and wherein X and X′ are different and further where is a double bond when X′ is N and a single bond when X′ is NH; Q represents H, alkoxyl, —NR 1 R 2 , F or Cl; Q 1 is absent when Z′ is N and when Z′ is C it represents H, alkoxyl, —NR 1 R 2 , F or Cl; A represents a five to ten membered single or multiple ring structure with heterocyclic N or O located at the ortho position, said ring including optional double bonds, substitutions and/or other heteroatoms and pharmaceutically acceptable derivatives thereof.

  本发明涉及新化合物、其制备方法及其在保护生物材料免受辐射损伤（辐射防护）方面的用途。本发明的首选化合物是式 II 所示的化合物，其结构如下：其中，W 代表 —N(R1R2)，其中 R1 和 R2 不全为氢，且它们可以一起形成 5、6 或 7 成员环结构，—NHN(R1R2)、—NHR3N(R1R2)、—NHR3OR2、—N(R3)R3OR2、—N(R1)R3OR3OR3、—OR3NR1R2、—OR3 或 W 代表哌啶基、哌嗪基、吗啉基、硫代吗啉基或二氮杂环庚烷基，每个基团可以选择地被 C1 到 C4 烷基、C2 到 C4 烯基、—N(CO)N(R1R2)、—N(CO)OR1、—N(CO)OR3OH、—(CO)NR1R2、—R3(CO)NR1R2、—R3OR1、—OR1、—N(R1R2) 或 —NH— 取代；R1 和 R2 相同或不同，选择自氢、C1 到 C4 烷基或 C2 到 C4 烯基；R3 是 C1 到 C4 烷基或 C2 到 C4 烯基基团或链；Z 相同或不同，代表 N 或 CH；Z′ 相同或不同，代表 N 或 C；X 代表 CH、N 或 NH，其中当 X 是 CH 或 N 时为双键，当 X 是 NH 时为单键；X′ 代表 N 或 NH，其中当 X 是 CH 或 N 时，X′ 为 NH，且 X 和 X′ 不同，进一步地，当 X′ 为 N 时为双键，当 X′ 为 NH 时为单键；Q 代表 H、烷氧基、—NR1R2、F 或 Cl；当 Z′ 为 N 时，Q1 不存在，当 Z′ 为 C 时，Q1 代表 H、烷氧基、—NR1R2、F 或 Cl；A 代表具有杂环 N 或 O 的五到十成员单环或多环结构，该环在邻位位置包括可选的双键、取代基和/或其他杂原子，以及其药学上可接受的衍生物。
• Imidazole derivatives and their use as modulators of cyclin dependent kinases
  申请人：Howard Steven

  公开号：US08598217B2

  公开（公告）日：2013-12-03

  The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+—O− or CR3; Y is N, N+—O− or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

  本发明提供了公式（I）的化合物及其盐、互变异构体、溶剂合物和N-氧化物；其中Q为CH或N；X为N、N+—O−或CR3；Y为N、N+—O−或CR3a；R1和R2独立地选择氢和各种取代基，如权利要求中所定义的；或者R1和R2与它们所连接的原子一起，链接形成一个选择性取代的4到7个成员的碳环或杂环芳香或非芳香环；R3选择氢和各种取代基；R3a选择氢和各种取代基，如权利要求中所定义的。还提供了含有公式（I）化合物的制药组合物、制备化合物的方法以及化合物的医药用途。公式（I）化合物具有作为CDK激酶抑制剂的活性，并且在治疗增殖性疾病，如癌症等方面是有用的。